You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Tocilizumab in recent polymyalgia rheumatica: how can we manage the interleukin-6 blockage?
Free
  1. Valérie Devauchelle1,
  2. Alain Saraux2
  1. 1Brest University and La Cavale Blanche Hospital—Rheumatology, Brest, France
  2. 2CHU Brest—Rheumatology, Bd Tanguy Prigent, Brest, France
  1. Correspondence to Professor Valérie Devauchelle, Brest University and La Cavale Blanche Hospital—Rheumatology, BD Tanguy Prigent, Brest 29609, France; valerie.devauchelle-pensec{at}chu-brest.fr

https://doi.org/10.1136/annrheumdis-2016-209607

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Thanks to Dr Moiseev et al1 for their very interesting opinions on the treatment of polymyalgia rheumatica (PMR) with tocilizumab (TCZ). In the TENOR study,2 for the first time, treatment other than glucocorticoid (GC) was able to control PMR. All patients received TCZ alone during 24 weeks. All parameters were improved: clinical symptoms, biological inflammation, patient's evaluation on disease activity, quality of life and imaging procedure.3 This highlighted the role of interleukin-6 (IL-6) in the pathogenesis of the PMR and probably in giant cell arteritis. IL-6 was first described for its role in adaptive immunity but it also plays a …

    View Full Text

    Linked Articles